Acute myeloid leukemia (AML) is characterized by the accumulation of immature blood cell precursors in the bone marrow. Pharmacologically overcoming the differentiation block in this condition is an attractive therapeutic avenue, which has only achieved success in a subtype of AML, acute promyelocytic leukemia (APL). Attempts to emulate this success in other AML subtypes have thus far been unsuccessful. Autophagy is a conserved protein degradation pathway with important roles in mammalian cell differentiation, particularly within the hematopoietic system. In this study we demonstrate the functional importance of autophagy in APL cell differentiation. We show that autophagy is increased during ATRA-induced granulocytic differentiation of the APL cell line NB4, and that this is associated with increased expression of LC3-II and GATE-16 proteins involved in autophagosome formation. Autophagy inhibition, using either drugs (chloroquine/3-methyladenine) or short-hairpin (sh)RNA targeting the essential autophagy gene ATG7, attenuates myeloid differentiation. Importantly, we show that enhancing autophagy promotes ATRA-induced granulocytic differentiation of an ATRA-resistant derivative of the non-APL AML HL60 cell line (HL60-Diff-R).
Introduction
The term 'acute myeloid leukemia' (AML) describes a heterogeneous group of clonal disorders of hematopoietic progenitor cells, all of which are characterized by the accumulation of immature blood cell precursors in the bone marrow and peripheral circulation. In addition to environmentally leukemogenic factors, a complex interplay of cytogenetic, genetic and epigenetic abnormalities contributes to AML pathogenesis, conferring on malignant cells an increased proliferation rate, resistance to apoptosis and a differentiation block [1] . AML is the most common acute leukemia in adults, with an incidence that increases with age. The MRC AML trials report an overall survival of 47% for patients under 60 years and 20% for those above 60 years [2] . These figures highlight that despite advances in molecular understanding of the condition, there is a need for improved and tolerable therapeutic strategies. 'Differentiation therapy' exploiting pharmacologic override of the cellular differentiation block observed in AML, is one attractive strategy with a favorable toxicity profile. Success with this approach has been achieved with the use of all-trans-retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia (APL) [3] .
APL is a distinct form of AML, accounting for approximately 10% of cases.
It is distinguished by a characteristic morphology, a potentially fatal coagulation defect at clinical presentation and chromosomal translocations involving the retinoid acid receptor alpha (RARα) gene on chromosome 17 [3] . At least nine driver translocations have been identified, with the most common being at t15;17, which fuses the promyelocytic leukemia (PML) gene with RARα [3] . The resultant PML-RARα fusion oncoprotein represses transcription and blocks granulocyte differentiation at the promyelocyte stage [3] . Therapeutic doses of ATRA, a physiologically active retinoid, restore normal differentiation through two distinct mechanisms: (i) de-repression of transcription [4] and (ii) degradation of the PML-RARα oncoprotein [5, 6] . Arsenic trioxide (ATO) is a second differentiating agent that has now been incorporated into the treatment of APL. When administered in combination with ATRA, ATO eliminates the need for cytotoxic chemotherapy in the treatment of low to intermediate-risk APL [7] .
Interestingly, ATO also increases the degradation of the PML-RARα protein [8] , 5 and this proteolysis is now thought to be critical for eradicating APL leukemiainitiating cells (LICs) and achieving long-term cures [5, 9] .
Autophagy is a degradative cellular process ubiquitously observed across the eukaryotic hierarchy. It allows the disposal of aged, redundant or damaged proteins, aggregates and organelles without steric limitation [10] . Cell contents targeted for autophagic degradation are sequestered within double-membraned autophagic vesicles known as 'autophagosomes', which are subsequently delivered to lysosomes and their contents degraded by resident proteases and hydrolases [11] . At a molecular level, autophagy is mediated by a family of AuTophaGy-related (ATG) proteins, which are sequentially recruited to the developing autophagosome membrane [12] . Membrane elongation is specifically dependent on two ubiquitination-like reactions: (i) the formation of an ATG5-ATG12 conjugate and (ii) the conjugation of phosphatidylethanolamine (PE) to the ATG8 homologues LC3, GATE-16 and GABARAP. These lipidated proteins are then incorporated into and stabilize autophagic vesicles at different stages of maturation [11, 13, 14] . Both conjugation reactions are catalyzed by the E1 ligase ATG7 -thought to be an essential component of autophagy machinery [11] .
As a pathway involved in protein turnover, autophagy plays an intrinsic role in mammalian development and differentiation [13, 15] . Within the hematopoietic system, autophagy is specifically involved in organelle clearance during reticulocyte differentiation [15] , lymphocyte differentiation [15] and plasma cell differentiation [16] . In addition, conditional hematopoietic cell deletion of Focal adhesion kinase (FAK) family interacting protein FIP200 -a key protein involved in autophagy activation, results in severe anemia [17] , while ATG7 deletion leads to a fatal myeloproliferation resembling AML [18] suggesting that autophagy may also be integral to normal myeloid differentiation.
Through poorly characterized mechanisms, both ATRA and ATO have been shown to induce autophagy in APL cells [19] [20] [21] [22] . This induction is thought to contribute to proteolysis of the PML-RARα oncoprotein [20, 22] , similar to the mechanism by which imatinib-induced autophagy degrades the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) [23] .
We investigated the role of autophagy in ATRA-mediated granulocytic differentiation of APL cells. We confirm that autophagy is upregulated upon 6 ATRA treatment and demonstrate induction of ATG8 homologues LC3 and GATE-16. Furthermore, we show that inhibition of autophagy with either drugs or targeted ATG7 knockdown attenuates APL cell differentiation. In addition, we show that pharmacologic autophagy induction facilitates the ATRA-mediated differentiation of non-APL, ATRA-resistant HL60-Diff-R AML cells, suggesting that targeting autophagy may represent a means of re-establishing differentiation in this aggressive cancer.
Materials and Methods

Cell lines & culture
NB4 cells were a gift from Prof. Estelle Duprez (INSERM, France). A differentiation-resistant variant of HL60 cells, HL60-Diff-R (HL60 genotype confirmed by LGC standards), were a gift from Prof. Tom Cotter (UCC, Ireland).
Cells were maintained at 37°C, 5% CO2 in RPMI 1640 (Sigma, Ireland R8758), 10% heat-inactivated fetal calf serum (Sigma F7524) and 1% Penicillin/Streptomycin (Gibco Ireland 15070-063). Cells were seeded at 2 x 10 5 cells/ml prior to treatment.
Primary APL cells
Following local ethics committee approval and informed consent, peripheral blood samples were obtained from two patients newly-presenting with APL.
Whole samples were gradient-separated using Histopaque-1077 (Sigma 10771) and mononuclear cells were extracted comprising a predominantly malignant population.
Drug treatments
ATRA (Sigma R2625) was diluted from a 1 mM stock in 100% ethanol.
Lysosomal function was inhibited with E64d (Sigma E8640) and pepstatin A methyl ester (Calbiochem 516485). Autophagy was inhibited with chloroquine (Sigma C6628) and 3-methyladenine (3-MA) (Sigma M9281). Autophagy was induced with lithium chloride (Sigma L9650) and rapamycin (Sigma R8781). 
Morphologic examination
Cells were cytospun onto glass slides and stained with Rapi-Diff (Braidwood Laboratories 22007, 22008, 22009) according to product guidelines.
Morphology was examined using an Olympus DP70 digital microscope (Mason Technology, Dublin, Ireland).
Western blotting
Cellular protein extracts were lysed in modified RIPA buffer (50 mM TrisHCl -pH 7.4, 150 mM NaCl, 0.25% sodium deoxycholate, 1% Igepal, 1 mM EDTA, 1x
Pefabloc, 1x Protease inhibitor cocktail, 1 mM Na3VO4, 1 mM NaF). Protein 
Quantitative PCR analysis
RNA extraction was performed using the miRCURY RNA Isolation Kit from Exiqon (Vedbaek, Denmark) according to the manufactures description. RNA was reverse-transcribed using the masterscript kit purchased from 5prime (Hilden, Germany). Quantitative PCR analysis of CEBPε and GSF3R mRNA was performed using TaqMan® reagents and the StepOnePlus qPCR system (Applied Biosystems, Zug, Switzerland). Raw Ct values were normalized to HMBS and to the untreated control of day 3 (∆∆Ct method). Gene Expression Assays for CEBPE and CSF3R were HHs00357657_m1 and Hs00167918_m1, respectively (Applied Biosystems, Rotkreuz, Switzerland). HMBS primer and probes have been described previously [24] .
Results
Autophagy is upregulated during ATRA-induced APL cell differentiation.
We investigated autophagic activity during the myeloid differentiation of APL cells. Human NB4 cells (PML-RARα +ve APL) were induced to differentiate along a granulocytic lineage with therapeutic doses of ATRA (1 μM In order to distinguish autophagy, we examined levels of a known marker LC3B. LC3B-I becomes conjugated to phosphatidylethanolamine (PE) to form LC3B-II, which is incorporated into autophagosome membranes. Other members of the ATG8 family of proteins, GABARAP and GATE-16/GABARAPL2, can also be incorporated into autophagosomes [14] . As differentiation proceeded, a decrease in LC3B-I protein levels was observed at day 1 by western blot. An increased level of LC3B-II was observed by day 2 and this was further enhanced in the presence of the lysosomal protease inhibitors E64d and pepstatin, both of which prevent autophagosomal turnover ( Figure 1B) . We detected increased GABARAP and GATE-16 levels, from day 2, with GATE-16 proving to be the most specific protein marker ( Figure 1B) , consistent with previously published data [25] .
We then quantified autophagic activity by flow cytometry using the Cyto-ID assay, which fluorescently tags autophagosomes [26] . A 1.8-fold increase in mean fluorescence intensity was detected in ATRA treated NB4 cells at day 3 ( Figure 1C ). Together, these data suggest that autophagic activity is increased during the ATRA-mediated granulocytic differentiation of APL cells.
Pharmacologic inhibition of autophagy attenuates the ATRA-induced differentiation of APL cells.
We then examined whether pharmacological inhibition of autophagy would interfere with in vitro leukemic cell differentiation. The anti-malarial compound chloroquine raises lysosomal pH, inhibiting the activity of resident enzymes and thus impeding completion of autophagy [27] . NB4 cells were incubated for four 
ATG7 is required for effective ATRA-mediated APL cell differentiation.
We then assessed whether a known autophagy regulator, ATG7, was important for granulocytic differentiation of APL cells. ATG7 was depleted by lentiviralmediated shRNA knockdown in NB4 cells. Knockdown in two distinct clones (shATG7_1 & shATG7_2) was evaluated at the protein level under basal conditions and following pharmacologic autophagy induction to ensure that the protein could be effectively depleted when autophagy is induced. Rapamycin directly inhibits mTOR, a master negative regulator of autophagy [29] . Lithium chloride (LiCl) lowers cytosolic inositol 1,4,5-triphosphate (IP3) levels and is a potent pharmacological inducer of autophagy [30] . Following treatment for 24 hours with either lithium or rapamycin, the ATG7-knockdown NB4 cells 
Discussion
In this study, we demonstrate that autophagy is upregulated during ATRAmediated granulocytic differentiation of APL cells. This is associated with an increase in LC3B-II and GATE-16 levels, consistent with their involvement in autophagosome formation [14] . We show that inhibition of autophagy, either pharmacologically or through targeted genetic knockdown of ATG7, impedes ATRA-mediated differentiation. Thus, we propose that the process of autophagy is an important mediator of ATRA's effects on APL cells, providing further support to recent data on leukemic cell differentiation [20] [21] [22] 31] .
ATG7 is a key enzyme in autophagic pathways, acting in both of the conjugation steps involved in autophagosome formation -the conjugation of ATG5 and ATG12, and the conjugation of ATG8 family members to phosphatidylethanolamine (PE) [18] . Previous studies in other cell and in vivo models have shown successful inhibition of autophagy by knockdown/deletion of ATG7 [32] . Within the hematopoietic system, the importance of ATG7 has been demonstrated in normal hematopoietic stem cell renewal, quiescence and remodeling, while also being involved in the differentiation of erythrocytes, lymphocytes and mast cells [13] . The importance of other autophagy regulators such as ULK1, ATG5, PI3KC3, SQSTM1 [20] , BECN1 [19] , DRAM-1 [31] and GATE-16 [21] for APL cell differentiation has been evaluated; however, the effect of ATG7 knockdown has not previously been examined. Our study thus establishes a novel and important role for ATG7 in APL differentiation and by inference, response to differentiation therapy.
It is now broadly accepted that ATRA exerts dual effects on APL cellsovercoming the repressive transcriptional effects of the PML-RARα oncoprotein and increasing its degradation [6] . Using synthetic retinoids capable of activating transcription but not protein degradation, these effects have been uncoupled, showing that while differentiation can occur in the absence of proteolysis, PML-RARα elimination is necessary to achieve long-term disease control [5] .
Operating without steric limitations, autophagy is the primary pathway available to cells for degrading large aggregated proteins. The chimeric PML-RARα protein (MW 110 kDa), is more prone to aggregation than either PML or RARα alone [22] . This leads to the formation of a large multimeric complex (669 kDa) [33] , which requires functioning autophagy for its degradation [20, 22] . While our data would be consistent with autophagy promoting PML-RARα proteolysis, we also show that lithium chloride, an autophagy inducer, potentiates the ATRAmediated granulocytic differentiation of AML cells that do not carry an abnormal RARα fusion protein. Thus, it is likely that autophagy plays a role in the extensive cellular remodeling that occurs in differentiating cells and is not solely involved in oncoprotein clearance.
There is now increasing data supporting a role for autophagy in cellular differentiation [15] . Within the hematopoietic system, murine studies have elucidated a critical role for autophagy in the removal of intracellular organelles from developing reticulocytes. Indeed, interference with several important autophagy genes (ULK1, ATG7, BNIPL3 or FIP200) results in severe red cell defects and anemia [17, 34] . Autophagy also participates in the differentiation of both B-and T-lymphocytes [35] , plasma cells [16] and monocytes [36] . Despite the confounding presence of an abnormal fusion oncoprotein, the ATRAmediated differentiation of APL cells in culture has long been used as a model for normal myelopoiesis [37] . Our study performed on a leukemic cell line model may have broader application, also suggesting a role for autophagy in normal myelopoiesis. It is possible that defects in autophagy may contribute to the differentiation block seen in malignancies such as AML. Conditional deletion of the ATG7 gene in the murine hematopoietic system results in an abnormal myeloid proliferation with dysplasia which is ultimately fatal -a condition very closely resembling AML [18] . In this study, using the promyeloblastic ATRAresistant HL60-Diff-R cell line, which does not carry the PML-RARα oncoprotein characteristic of APL, we show that treatment with lithium chloride in combination with ATRA promoted granulocytic differentiation, suggesting that induction of autophagy may overcome the differentiation block in these cells.
Lithium has shown long-standing clinical efficacy in the treatment of mood disorders. Mechanistically, the lithium ion competitively inhibits magnesium binding sites on dependent enzymes [38] . Following observations that patients undergoing lithium therapy developed granulocytosis [39] , in vitro studies in the early 1990s showed that combinations of lithium with ATRA induced the differentiation of human myeloid leukemic cell lines [40] . This effect was attributed to either increased RARα pools or to the inhibitory actions of lithium on glycogen synthase kinase 3β (GSK3β), a serine/threonine kinase with well-characterized roles in differentiation [38, [41] [42] [43] . Lithium-induced autophagy has been associated with neuroprotective effects in conditions that are attributable to the accumulation of abnormal mutant proteins e.g. huntingtin in Huntington's disease and α-synuclein in Parkinson's disease [38, 44] .
Lithium's effects on autophagy in neuronal cells have been reported to be mediated by inhibition of the enzyme inositol monophophatase (IMP) and depletion of free inositol [30] . Lithium has also been reported to augment signaling through the cAMP pathway (reviewed in [45] ). Interestingly, a recent study found that augmentation of this pathway with 8-CPT-cAMP, upregulated p62/SQSTM1 and LC3 and promoted ATRA induced differentiation of the resistant cell line NB4-LR1 [46] .
It is therefore important to acknowledge that while lithium is an autophagy inducer, the pro-differentiation effects of lithium observed in our experiments are likely to be multi-factorial, with input from several signaling pathways. However, given our data and those of others supporting an important role for autophagy in differentiation, we propose that autophagy induction by lithium, may contribute to its pro-differentiation effects, and this has not been previously recognized in the literature.
Autophagy is a known cellular response to stress -enabling survival in times of nutrient depletion or oxidative stress [47] . However, autophagy has also been linked to the induction of a form of programmed cell death distinct from classical apoptosis [48] . The role of autophagy in cancer is complex and appears to be context-dependent. While in normal cells autophagy has a tumorsuppressive function, cancer cells are often capable of using survival autophagy to sustain their metabolism in hypoxic or nutrient-depleted environments [49] .
Indeed, cancer cells have been observed to upregulate autophagy in response to chemotherapeutic stress and studies of several cancer models -including chronic myeloid leukemia [50] , have shown that autophagy inhibition increases chemoefficiency [48, 51] . As a result, several clinical trials, combining the autophagy inhibitor chloroquine or its sister drug hydroxychloroquine, with conventional chemotherapy are currently underway in both solid and hematologic malignancies [52] . Conversely, studies in hematologic malignancies have shown that several anti-tumor agents promote autophagic cell death, and that this is critical to their efficacy [48, 53] . Our study supports the concept that autophagy induction may be of clinical benefit through promoting terminal differentiation and subsequent cell death. Further studies with AML clinical samples and other autophagy inducers are warranted.
In summary, this study suggests that autophagy is a critical component of ATRA's differentiating effects in APL and that pharmacologic autophagy induction in this context may potentiate the ATRA-mediated differentiation of non-APL AML cells. We expect that such a combination therapy would likely be minimally cytotoxic to normal cells and would be well tolerated by elderly patient populations, providing at least transient disease control in the absence of chemotherapy. The exact mechanisms through which ATRA activates autophagy remain to be elucidated and we expect that future studies will address this issue so that we can understand how best to target this process for patient benefit.
Conclusion
This study demonstrates a key role for autophagy in myeloid differentiation.
Importantly, these data show that differentiation can be achieved in ATRA resistant AML cells, by co-treatment with lithium. Lithium induces autophagy and diminishes colony regrowth. As pharmacologically overcoming the differentiation block in AML would be a major therapeutic advance, the possibility of achieving this with autophagy inducers is an attractive area for future intervention. 
